QIAGEN uvedl na trh IPA Investigator a QIAGEN Discovery Platform, nástroje využívající AI pro rychlejší analýzu biologických a genomických dat a automatizaci objevování léčiv.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible.
The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows.
The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights (QDI), whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence.
As researchers increasingly use AI to analyze growing volumes of biological and genomic data, speed alone is not enough. QIAGEN combines AI with expert-reviewed biological, genomic and clinical information so scientists can examine the evidence behind the results.
“AI can deliver an answer in seconds, but in science, speed without evidence can create false confidence,” said Dominic John, Vice President and Head of QIAGEN Digital Insights. “Our approach is to combine the speed of AI with expert-curated biomedical knowledge and traceable scientific evidence so researchers can examine the evidence behind the results and evaluate them for themselves.”
IPA Investigator allows scientists to ask questions about their data in natural language. It can identify relevant biological relationships, recommend analyses and carry them out within IPA. Researchers can then connect their own experimental data with existing biological knowledge to better understand disease, identify potential drug targets and decide what to investigate next.
At the University of Bergen in Norway, researchers tested IPA Investigator using complex datasets that deliberately introduced misleading sample comparisons.
“We deliberately introduced misleading comparisons to see how IPA Investigator would respond. It identified the problem, cautioned us against overinterpreting the results and suggested a better experimental design,” said Dr. Simona Chera, Professor at the University of Bergen.
QIAGEN is also introducing the QIAGEN Discovery Platform, which enables the integration of AI with QIAGEN’s biomedical knowledge base and molecular data to support drug discovery. The platform is designed to help researchers identify potential drug targets and biomarkers, generate research hypotheses and automate parts of the discovery process.
The launches are part of a broader rollout of AI across QIAGEN Digital Insights, including AI-powered translation in QIAGEN Clinical Insight (QCI) Interpret and machine learning combined with expert-reviewed information in Franklin by QIAGEN.
For more information about QIAGEN Digital Insights, visit: https://digitalinsights.qiagen.com/.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of the U.S. federal securities laws. These statements include, among others, statements regarding QIAGEN’s products, product development and launches, regulatory approvals, market opportunities and future business performance. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the development and commercial success of new products, regulatory approvals, competition, changes in customer demand and funding, economic and market conditions, supply chain disruptions, cybersecurity incidents, litigation and other risks described under “Risk Factors” in QIAGEN’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. QIAGEN undertakes no obligation to update any forward-looking statement except as required by law.
QIAGEN získal od FDA povolení pro nový panel QIAstat-Dx BCID GN Plus AMR, který za zhruba hodinu odhalí 13 gramnegativních patogenů a 18 markerů rezistence.
Key Takeaways QGEN's new panel detects 13 gram-negative pathogens and 18 antimicrobial resistance markers.QIAGEN's two QIAstat-Dx panels cover 33 pathogen targets and 28 resistance markers in about one hour.QGEN also launched QIAmini, its third new sample preparation system introduced in 2026. QIAGEN N.V. (QGEN - Free Report) announced that U.S. laboratories now have access to its complete QIAstat-Dx bloodstream infection portfolio following FDA clearance of a new panel. The new QIAstat-Dx BCID GN Plus AMR Panel identifies gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi.
The latest development expands the company’s QIAstat-Dx infectious disease testing menu in the United States, which already includes tests for respiratory and gastrointestinal infections, as well as meningitis and encephalitis.
Importance of QGEN’s New Bacteria Detection PanelBloodstream infections can progress rapidly and may lead to sepsis, a life-threatening response to infection that can result in organ failure and death. According to the U.S. Centers for Disease Control and Prevention, about 1.7 million adults in the United States develop sepsis each year, with at least 350,000 dying during hospitalization or being discharged to hospice. Faster identification of the cause of an infection can give clinicians important information to help guide treatment decisions.
The new Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers. More recently, QIAGEN earned FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, which detects 20 gram-positive bacterial and fungal pathogen targets as well as a broad pan-gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples.
Together, the two panels cover 33 pathogen targets and 28 antimicrobial resistance markers. The gram-negative panel covers 13 pathogen targets and 18 resistance markers, while the gram-positive and fungal panel covers 20 pathogen targets and 10 resistance markers. Both deliver results in about one hour.
More Developments Within QIAGENThis month, QIAGEN announced the launch of QIAmini, a compact automated sample preparation system that offers research laboratories a time-saving and cost-efficient alternative to manual sample processing. It is the third new QIAGEN sample preparation system launched in 2026, following QIAsprint Connect for high-throughput research sample processing and QIAsymphony Connect for medium-throughput sample processing.
QGEN’s Industry ProspectsAccording to Fortune Business Insights, the bloodstream infection testing market was valued at $801 million in 2025 and is projected to witness a CAGR of 4.6% through 2034. The market is heavily influenced by rapid molecular diagnostics, automation in clinical microbiology, AI-assisted pathogen detection technologies, as well as the rising adoption of syndromic testing panels and real-time antimicrobial resistance monitoring systems.
Updates From QGEN PeersApart from QIAGEN, several key players in the bloodstream infection testing industry have recently made notable advancements.
Bruker (BRKR - Free Report) has introduced new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics and oligonucleotide analysis. The company made the announcement at the Human Proteome Organization World Congress 2026. This month, Bruker also received a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (“NMR”) instrumentation at the Pines Magnetic Resonance Center, which exceeds $6 million. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation.
Becton, Dickinson and Company (BDX - Free Report) , or BD, announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next-generation pharmacy automation robot. The system is designed to help manage the growing complexity of specialty therapies and refrigerated medicines in high-volume, centralized outpatient pharmacies. BD’s STANCE clinical trial evaluating GalaFLEX LITE Scaffold in breast revision surgery for capsular contracture reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites.
Thermo Fisher Scientific (TMO - Free Report) recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell lines and is available in liquid and dry powder media formats. The company also introduced the Multiskan Ease Absorbance Microplate Reader to support protein quantification, enzyme-linked immunosorbent assays, cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Thermo Fisher also announced the EMPAD G2 detector, designed to help researchers analyze materials in greater detail.
QIAGEN představil QIAmini, kompaktní automatizovaný systém pro přípravu vzorků určený pro menší laboratorní série. V testovaných pracovních postupech zkrátil ruční čas o více než 80 %.
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alternative to processing samples by hand.
QIAmini is designed primarily for academic laboratories and other research customers processing smaller sample batches that do not require larger automated systems. QIAGEN estimates the addressable market at more than 100,000 potential instrument placements worldwide. Automation can reduce repetitive manual work and free up skilled laboratory staff, which can be difficult to recruit and retain.
QIAmini is a benchtop system with a footprint about the size of a sheet of printer paper. It processes up to eight samples per run and automates DNA and RNA extraction and purification. Across evaluated workflows, QIAmini reduced hands-on time by over 80%.
“Automation should not depend on batch size,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIAmini gives labs processing smaller batches a practical way to replace repetitive manual work with automation. It also expands our automation portfolio from small batches to high-throughput research and clinical testing.”
Five dedicated QIAmini kits support DNA and RNA sample processing from biological materials such as tissue, cells, cheek swabs, whole blood, body fluids and stool. Applications include PCR, digital PCR and next-generation sequencing (NGS).
QIAmini is the third new QIAGEN sample preparation system launched in 2026. It follows QIAsprint Connect for high-throughput research sample processing and QIAsymphony Connect for medium-throughput sample processing in research and clinical laboratories.
For more information about QIAmini, visit https://www.qiagen.com/qiamini or register for the Qrious Show on October 8 at https://www.qiagen.com/knowledge-and-support/knowledge-hub/events-and-webinars/qiamini
QIAmini is intended for research use only and not for use in diagnostic procedures.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of the U.S. federal securities laws. These statements include, among others, statements regarding QIAGEN’s products, product development and launches, regulatory approvals, market opportunities and future business performance. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the development and commercial success of new products, regulatory approvals, competition, changes in customer demand and funding, economic and market conditions, supply chain disruptions, cybersecurity incidents, litigation and other risks described under “Risk Factors” in QIAGEN’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. QIAGEN undertakes no obligation to update any forward-looking statement except as required by law.
QIAGEN rozšiřuje testovací menu a automatizaci; nové systémy mají ve druhé polovině roku 2026 přidat asi 2 procentní body k postupnému zlepšení tržeb. Firma ale čelí opatrným výdajům zákazníků a silné konkurenci.
Key Takeaways QIAGEN is expanding test menus and automation, with new systems supporting second-half 2026 sales growth. Partnerships are broadening QIAGEN's assay, automation and digital capabilities across key markets. QGEN faces cautious customer spending and competition that may delay platform adoption. QIAGEN N.V. (QGEN - Free Report) is well positioned for growth in the upcoming quarters, supported by continued test menu expansion. Meanwhile, strategic partnerships support assay development and create opportunities for recurring consumables revenues across clinical, research and biopharma markets. However, cautious customer spending, weaker research funding and intense competition may limit near-term growth and delay the adoption of new platforms.
In the past year, shares of this Zacks Rank #3 (Hold) company have lost 7.8% against the industry’s 21.3% growth. The S&P 500 composite has seen a 17.9% rise in the same time frame.
The leading provider of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA has a market capitalization of $9 billion. QIAGEN has earnings yield of 5.56% against the industry’s negative 15.63% yield.
Let’s delve deeper.
Tailwinds for QGEN Stock Progress With Test Menu Expansion: QIAGEN continues to invest in menu breadth and workflow automation across core platforms. QIAstat-Dx expanded into bloodstream infection testing in Europe with two BCID panels covering 33 pathogens and 28 antimicrobial-resistance markers in about one hour. The Gastrointestinal panel also supported testing during the U.S. Cyclospora outbreak.
In sample preparation, QIAsymphony Connect was launched, while QIAsprint Connect began customer placements in second-quarter 2026. QIAmini remains on track for launch in fall 2026. Management expects new Sample Technologies systems and other product launches to contribute approximately two percentage points to the sequential improvement in second-half 2026 sales.
Strategic Collaborations to Drive Growth: QIAGEN uses strategic partnerships to expand assay development, automation and digital capabilities across its portfolio. In companion diagnostics, pharmaceutical collaborations support multi-year co-development programs and recurring consumables opportunities as associated therapies advance. The company is also working with DiaSorin and Inpeco on a fully automated QuantiFERON workflow targeted for the second half of 2027. In digital PCR, its collaboration with Hamilton is extending QIAcuity automation for cell and gene therapy applications.
QDI is also partnering with NVIDIA to combine curated biomedical knowledge with accelerated computing and AI tools for drug discovery. These collaborations broaden QIAGEN’s platform capabilities and support adoption across clinical, research and biopharma workflows.
Image Source: Zacks Investment Research
What Ails QGEN Stock?Macro Risks and Demand Sensitivity: QIAGEN remains exposed to fluctuations in testing demand, research funding and customer capital spending across its global markets. In the second quarter of 2026, instrument sales declined at a low-teens CER rate as U.S. Life Sciences customers remained cautious.
NIH funding in the first half of 2026 remained below year-ago levels despite sequential improvement in the second quarter. PCR/Nucleic Acid Amplification sales fell 8% at CER, reflecting weaker OEM demand and lower sales of other PCR products. These trends indicate that research funding and capital spending remain important variables for near-term growth, particularly in Life Sciences markets.
Competitive Intensity: QIAGEN operates in highly competitive molecular testing, sample preparation and bioinformatics markets, where established workflows may make share gains and platform conversions more difficult. This is particularly relevant as the company introduces new automation systems, syndromic testing panels and digital PCR offerings that depend on customer adoption and subsequent consumables pull-through. Competitive alternatives can lengthen sales cycles and limit the pace at which new platforms gain scale. Over time, QIAGEN’s growth will depend on converting product launches into sustained placements and recurring consumables demand across its core markets.
QGEN Stock Estimate TrendsThe Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $2.43 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $2.14 billion, which indicates a modest 2.2% rise from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical, flaunting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.
QIAGEN získal od FDA schválení pro QIAstat-Dx BCID GPF Plus AMR Panel, první panel platformy QIAstat-Dx pro diagnostiku krevních infekcí. Test odhalí 20 gram-pozitivních bakteriálních a houbových cílů i široký pan gram-negativní cíl spolu s 10 markery rezistence z pozitivní hemokultury asi za hodinu.
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is available in more than 100 countries and with more than 5,200 cumulative placements as of the end of 2025.
The QIAstat-Dx BCID GPF Plus AMR Panel detects 20 gram-positive bacterial and fungal pathogen targets as well as a broad pan gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples in about one hour. The rapid identification of pathogens and resistance gene markers can support informed treatment decisions, antimicrobial stewardship and infection prevention measures.
Bloodstream infections are associated with significant morbidity and mortality and can rapidly progress to sepsis, a life-threatening reaction to an infection that causes your immune system to harm healthy tissues and organs. An estimated 1.7 million adults in the U.S. develop sepsis each year1, highlighting the importance of providing clinicians with timely diagnostic information.
“Every hour, even minutes, count with bloodstream infections,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “This clearance gives U.S. laboratories a fast and integrated way to identify pathogens and key genetic antimicrobial resistance markers, supporting more informed treatment decisions and responsible antibiotic use. It also establishes the first member of a broader QIAstat-Dx bloodstream infection panel family planned for the U.S.”
The QIAstat-Dx system integrates sample preparation, multiplex PCR testing and data analysis into a single workflow. It is designed to provide rapid and easy-to-interpret results while reducing hands-on time for laboratory professionals.
The FDA clearance also lays the foundation for the continued expansion of QIAGEN’s bloodstream infection testing portfolio in the U.S. A complementary QIAstat-Dx BCID GN Plus AMR Panel, designed to detect gram-negative pathogens and associated genetic antimicrobial resistance markers, is currently under FDA review.
QIAGEN has been consistently expanding the QIAstat-Dx menu for the U.S., broadening the platform across four major infectious disease areas: respiratory, gastrointestinal, central nervous system and now bloodstream infections. The portfolio includes the QIAstat-Dx Respiratory Panel Plus, the QIAstat-Dx Respiratory Panel Mini, the QIAstat-Dx Gastrointestinal Panel 2, the QIAstat-Dx GI Panel 2 Mini B, the QIAstat-Dx GI Panel 2 Mini B&V, the QIAstat-Dx Meningitis/Encephalitis Panel and the newly FDA-cleared QIAstat-Dx BCID GPF Plus AMR Panel. This reflects QIAGEN's strategy of building a comprehensive infectious disease testing menu on a single integrated platform.
For more information about the QIAstat-Dx BCID GPF Plus AMR Panel and the QIAstat-Dx system, visit www.qiagen.com/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to QIAGEN's filings with the U.S. Securities and Exchange Commission.
1 Centers for Disease Control and Prevention (CDC). About Sepsis. Available at: https://www.cdc.gov/sepsis/about/index.html (accessed August 2026).
Qiagen oznámil za 2. čtvrtletí tržby 535 mil. USD a upravený zředěný EPS 0,62 USD, oba nad výhledem. Firma potvrdila celoroční výhled růstu tržeb 1 % až 2 %.
Strategic Buy Lights Up This Biotech Stock: Time to Invest?Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates. Adjusted diluted earnings per share were $0.62, exceeding guidance of at least $0.60 at constant exchange rates.
Chief Executive Officer Thierry Bernard said the company’s growth pillars rose 5% at constant exchange rates during the quarter, led by Sample Technologies, QIAcuity digital PCR and QIAGEN Digital Insights. He said QuantiFERON latent tuberculosis testing returned to growth despite a significant decline in U.S. immigration testing demand, while QIAstat-Dx faced a difficult comparison in respiratory testing.
Get Qiagen alerts:
Product-group performance varied Sample Technologies sales increased 9% at constant exchange rates, supported by automated consumables and higher instrument sales compared with the prior-year period. Diagnostic Solutions revenue declined 2% at constant exchange rates. Within that segment, QuantiFERON grew 1%, as demand across most testing groups outweighed lower immigration testing demand in the U.S. and Middle East.
QIAstat-Dx sales fell 7% at constant exchange rates. Growth in gastrointestinal and meningitis panels was offset by lower respiratory-panel sales against a strong prior-year comparison. PCR and nucleic acid amplification sales declined 8%, although QIAcuity delivered double-digit growth driven by consumables demand. The growth in QIAcuity was more than offset by weaker OEM demand, according to Chief Financial Officer Roland Sackers.
Genomics and next-generation sequencing sales rose 2% at constant exchange rates. QIAGEN Digital Insights posted solid single-digit growth, while consumables for universal NGS panels used on third-party sequencers grew more than 20%. Lower sales of other genomics products moderated the segment’s overall growth rate.
Americas sales rose 1% at constant exchange rates, including 2% growth in North America. EMEA sales declined 2%, with gains in Spain, Belgium and Poland offset by declines in Germany, France and Italy. Asia-Pacific sales declined 2%, though the region excluding China grew at a low-single-digit rate and Japan posted high-teens growth. China sales declined in the low teens year over year, but improved sequentially at a double-digit percentage rate. Margins and cash flow remained high Adjusted operating income declined 2% to $157 million, while the adjusted operating margin was 29.4%, compared with 29.9% in the second quarter of 2025. Sackers said disciplined cost management and efficiency measures helped offset product-mix-related pressure on gross margin. The adjusted cost margin was 66.2%, down from 66.7% a year earlier.
The operating margin improved by 200 basis points sequentially from 27.4% in the first quarter. Qiagen’s adjusted tax rate was 18%, within its 17% to 18% target range.
Operating cash flow totaled $301 million for the first six months of 2026, unchanged from the same period in 2025. The figure included approximately $20 million in cash payments tied to efficiency and restructuring programs, as well as a planned inventory increase ahead of product launches. Days sales outstanding improved to approximately 55 days from 57 days at the end of 2025, while days inventory outstanding increased to 153 from 149.
The company completed a $500 million synthetic share repurchase in January and paid an approximately $72 million annual dividend in July. The dividend rose 40% to $0.35 per share from $0.25 in 2025.
New launches underpin second-half expectations Bernard highlighted progress in the company’s automation portfolio, including the commercial launch of QIAsymphony Connect and early placements of QIAsprint Connect. QIAmini remains scheduled for a fall launch, with beta field testing in North America expected to begin in coming weeks.
In diagnostics, Qiagen launched two QIAstat-Dx bloodstream infection panels in Europe that collectively detect 33 pathogens and 28 antimicrobial resistance markers in about one hour. Bernard said the company expects FDA approval for the panels by year-end. Qiagen also expects its complicated urinary tract infection panel to be available in Europe during the second half of 2027.
The company plans to launch new QIAcuity gene-expression assays and a multiplex kit for up to 12 RNA targets in a single reaction during the second half of 2026. It is also working with DiaSorin and Inpeco on a fully automated QuantiFERON Sample to Insight workflow, targeted for launch in the second half of 2027.
Guidance reaffirmed; strategic review continues Qiagen reaffirmed its full-year outlook for constant-exchange-rate sales growth of about 1% to 2% and adjusted diluted EPS of at least $2.43. For the third quarter, the company forecast sales growth of approximately 1% to 2% at constant exchange rates and adjusted diluted EPS of at least $0.62.
Sackers said the company expects sales growth to improve from a 1% decline in the first half to roughly 3% to 4% in the second half. Management cited the end of headwinds from discontinued NeuMoDx and bioinformatics portfolios, contributions from recent product launches, Parse single-cell analysis performance ahead of its approximately $40 million 2026 sales target, and modestly improving U.S. life-science funding conditions.
Bernard said Qiagen’s CEO search and strategic review are complementary but independent processes. He reiterated that the CEO transition is expected during the second half of 2026 and said the company will continue evaluating options intended to increase shareholder and stakeholder value.
About Qiagen (NYSE:QGEN)Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Qiagen Right Now?Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Qiagen ve 2. čtvrtletí zvýšil tržby na 535,04 mil. USD, nad odhady, a EPS činil 0,62 USD. Klíčové bylo i silné překonání u Sample Technologies: 182 mil. USD, +9,6 % meziročně.
For the quarter ended June 2026, Qiagen (QGEN - Free Report) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $527.94 million, representing a surprise of +1.35%. The company delivered an EPS surprise of +3.33%, with the consensus EPS estimate being $0.60.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $32 million versus the four-analyst average estimate of $36.58 million. The reported number represents a year-over-year change of -5.9%.Sales by Product Groups- Diagnostic solutions- QuantiFERON: $131 million versus $127.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.6% change.Sales by Product Groups- Diagnostic solutions- Other: $40 million versus the three-analyst average estimate of $29.5 million. The reported number represents a year-over-year change of 0%.Sales by Product Groups- Other: $15 million versus $14.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.8% change.Sales by Product Groups- PCR / Nucleic acid amplification: $74 million versus $69.7 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.Sales by Product Groups- Genomics / NGS: $61 million versus $59.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.Sales by Product Groups- Diagnostic solutions: $204 million versus the three-analyst average estimate of $202.46 million. The reported number represents a year-over-year change of -1%.Sales by Product Groups- Sample technologies: $182 million compared to the $181.19 million average estimate based on three analysts. The reported number represents a change of +9.6% year over year.View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned +9.3% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States.
More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis, a foodborne parasite that can cause prolonged diarrhea and other gastrointestinal symptoms. The parasite is not detected through routine stool culture and requires specialized diagnostic methods, including molecular testing.
QIAGEN's Sample to Insight portfolio supports laboratories across the molecular testing continuum, from syndromic diagnostics and digital PCR to next-generation sequencing (NGS):
The FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes Cyclospora cayetanensis as a standard target within its 16-target menu for bacterial, viral and parasitic pathogens. The fully integrated syndromic test delivers results in about an hour, enabling laboratories to test for Cyclospora alongside other common causes of gastrointestinal illness from the initial patient sample. For research use only, QIAGEN offers the digital PCR Microbial DNA Detection Assay targeting Cyclospora cayetanensis for use with the QIAcuity digital PCR system, supporting highly sensitive detection in research and public health applications. QIAGEN's sequencing portfolio also includes the PulseNet-approved QIAseq FX DNA Library Prep Kit for research use only with any NGS sequencer. This kit is designed to support “shotgun sequencing workflows” that analyze all DNA in a sample to help identify and characterize foodborne pathogens for PulseNet, the U.S. public health laboratory network that detects and investigates foodborne disease outbreaks. “The current rise in cyclosporiasis cases highlights the need for rapid, reliable detection to support timely patient care and effective public health action,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIAGEN is ready to support laboratories and public health authorities worldwide with molecular testing technologies that help detect infections, guide investigations and strengthen responses to emerging disease threats.”
Further information about QIAGEN's molecular testing solutions supporting clinical diagnostics, research and public health laboratories is available through local QIAGEN representatives or the QIAGEN Customer Care team on www.qiagen.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
QIAGEN v Evropě uvedla panel QIAstat-Dx BCID GN Plus AMR certifikovaný podle CE-IVDR pro rychlou detekci 13 gramnegativních patogenů a 18 markerů AMR z pozitivních hemokultur za přibližně hodinu.
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe.
The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It complements the recently launched QIAstat-Dx BCID GPF Plus AMR Panel in Europe, extending QIAGEN's bloodstream infection testing coverage across gram-positive bacteria, gram-negative bacteria, fungi and key AMR markers. Together, the two panels detect 33 pathogen targets and 28 AMR markers, enabling rapid identification of the most clinically relevant bloodstream pathogens and resistance mechanisms to support earlier pathogen identification and clinical decision-making.
“Every hour matters when treating bloodstream infections, particularly when AMR is involved,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Together, our complementary BCID panels provide comprehensive molecular coverage of the pathogens and resistance mechanisms most relevant to bloodstream infections. By delivering results in about one hour, they help laboratories support faster treatment decisions, antimicrobial stewardship and effective infection control.”
Gram-negative pathogens are among the leading causes of bloodstream infections and are frequently associated with AMR, one of the world's most significant public health threats. AMR occurs when bacteria develop mechanisms that render antibiotics ineffective, making infections more difficult to treat and increasing the risk of severe illness and death. In bloodstream infections, delays in identifying resistant pathogens can postpone appropriate therapy, while the growing burden of beta-lactam resistance driven by extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing organisms underscores the need for rapid and accurate detection. With broad coverage of key beta-lactam resistance mechanisms, the QIAstat-Dx BCID GN Plus AMR Panel provides rapid, actionable molecular insights to support optimized treatment decisions and infection control.
The QIAstat-Dx BCID GN Plus AMR Panel is CE-IVDR certified and available in applicable markets. Regulatory review by the U.S. Food and Drug Administration is underway.
QIAGEN's CE-IVDR-certified QIAstat-Dx menu in Europe spans key syndromic testing areas, including respiratory infections, gastrointestinal infections, central nervous system infections through its meningitis / encephalitis panel and bloodstream infection testing. With the addition of the BCID GN Plus AMR Panel, the QIAstat-Dx platform now provides comprehensive bloodstream infection testing through complementary gram-positive and gram-negative panels. Built around rapid, cartridge-based molecular testing, QIAstat-Dx integrates sample preparation, molecular analysis and result interpretation into a streamlined workflow, helping laboratories generate clinically relevant insights across a growing range of infectious disease applications.
QIAstat-Dx systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.
For more information about the QIAstat-Dx BCID GN Plus AMR Panel and the QIAstat-Dx system, visit https://www.qiagen.com/de-us/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
